Literature DB >> 9300551

Linear B-cell epitopes in the N-terminus of L2 of bovine papillomavirus type 4.

G Knowles1, G J Grindlay, M S Campo, L M Chandrachud, B W O'Neil.   

Abstract

The minor capsid protein L2 of bovine papillomavirus type 4 (BPV-4) is a very effective prophylactic vaccine which induces the production of virus neutralising antibodies and prevents virus-induced papillomatosis. The virus neutralising activity resides in the first 200 N-terminal amino acids of L2 (L2a). To further investigate the humoral immune response to L2, and the role it plays during infection and in prophylactic vaccination, the presentation of B-cell linear epitopes of L2a has been analysed in calves infected with the virus but not vaccinated, and in calves vaccinated with virus, L2a or E7. Several B-cell epitopes have been identified in L2a by the use of overlapping peptides; the epitopes varied in the different groups of animals, indicating that the epitopes presented by denatured L2 are not presented by the virus, and that therefore, although responsible for L2 vaccine-induced immunity, they may play little role in naturally acquired immunity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9300551     DOI: 10.1016/s0034-5288(97)90207-1

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  5 in total

1.  A multimeric L2 vaccine for prevention of animal papillomavirus infections.

Authors:  Subhashini Jagu; Nicole Malandro; Kihyuck Kwak; Hang Yuan; Richard Schlegel; Kenneth E Palmer; Warner K Huh; M Saveria Campo; Richard B S Roden
Journal:  Virology       Date:  2011-09-13       Impact factor: 3.616

2.  Production and characterization of a novel HPV anti-L2 monoclonal antibody panel.

Authors:  S M Bywaters; S A Brendle; J Biryukov; J W Wang; J Walston; J Milici; R B Roden; C Meyers; N D Christensen
Journal:  Virology       Date:  2018-08-28       Impact factor: 3.616

3.  Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.

Authors:  Ratish Gambhira; Subhashini Jagu; Balasubramanyam Karanam; Patti E Gravitt; Timothy D Culp; Neil D Christensen; Richard B S Roden
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

Review 4.  Papillomavirus prophylactic vaccines: established successes, new approaches.

Authors:  M Saveria Campo; Richard B S Roden
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

Review 5.  Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.

Authors:  Balasubramanyam Karanam; Subhashini Jagu; Warner K Huh; Richard B S Roden
Journal:  Immunol Cell Biol       Date:  2009 May-Jun       Impact factor: 5.126

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.